Jaguar Health Explores Strategic Alternatives for Rare Disease Program

Jaguar Health's Board of Directors has initiated a process to explore strategic alternatives aimed at maximizing shareholder value. This review is aligned with the anticipated completion of clinical work for a New Drug Application (NDA) filing for its crofelemer-based drug candidate for rare intestinal failure diseases. Potential alternatives include mergers, acquisitions, partnerships, and licensing arrangements. The company emphasizes its commitment to the crofelemer development program, which has shown promising results in clinical trials for conditions like microvillus inclusion disease and short bowel syndrome.